Perrigo Company plc (PRGO) Stock Analysis
Recovery setup
Healthcare · Drug Manufacturers - Specialty & Generic
Sell if holding. Engine safety override at $10.90: Quality below floor (3.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10 and A.R:R 2.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 17%; Below-average business quality; Below long-term trend.
Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments. It offers upper respiratory products, including... Read more
Sell if holding. Engine safety override at $10.90: Quality below floor (3.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10 and A.R:R 2.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 17%; Below-average business quality; Below long-term trend. Chart setup: Death cross but MACD improving, RSI 47. Score 5.0/10, moderate confidence.
Passes 6/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, earnings proximity 50d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: aggressive.
Recent developments
updated 2026-06-12Recent Developments — Perrigo Company plc
Latest news
- NEWS Cramer Says Credo Technology Is 'Just So Good' — But Warns This Healthcare Name Is A 'Value Trap' — benzinga Jun 15, 2026 neutral
- NEWS Watching Perrigo; Shares See Volume, Traders Circulate Unconfirmed M&A Blog Report Saying STADA And CapVest Are Launchin — benzinga Jun 10, 2026 neutral
- NEWS Mission Produce Posts Downbeat Q2 Earnings, Joins Ideaya Biosciences, Perrigo And Other Big Stocks Moving Lower In Tuesd — benzinga Jun 9, 2026 negative
- NEWS Perrigo Appoints Albert A. Manzone Interim President, CEO, Effective Immediately, Succeeding Patrick Lockwood-Taylor; Re — benzinga Jun 8, 2026 neutral
- NEWS Earnings Scheduled For May 6, 2026 — benzinga May 6, 2026 neutral
Generated 2026-06-17T09:31:49Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers·1 ceiling hit
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Unprofitable operations — net margin -43.5%. Quality floor flags this regardless of sector context.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $10.90: Quality below floor (3.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10 and A.R:R 2.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 17%; Below-average business quality; Below long-term trend. Chart setup: Death cross but MACD improving, RSI 47. Prior stop was $10.14. Score 5.0/10, moderate confidence.
Take-profit target: $14.03 (+28.7% upside). Prior stop was $10.14. Stop-loss: $10.14.
Quality below floor (3.0 < 4.0).
Perrigo Company plc trades at a P/E of N/A (forward 4.7). TrendMatrix value score: 9.2/10. Verdict: Sell.
10 analysts cover PRGO with a consensus score of 3.8/5. Average price target: $17.
What does Perrigo Company plc do?Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and...
Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments. It offers upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and oral electrolyte beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. The company also offers healthy lifestyle products, such as smoking cessation and well-being products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women's health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; and other miscellaneous self-care products. It sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, and Compeed brands. The company also offers contract manufacturing services. It sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.